MARKET

CINGW

CINGW

Cingulate
NASDAQ
0.0161
+0.0001
+0.63%
Closed 10:51 05/15 EDT
OPEN
0.0189
PREV CLOSE
0.0160
HIGH
0.0189
LOW
0.0161
VOLUME
4.01K
TURNOVER
--
52 WEEK HIGH
0.1750
52 WEEK LOW
0.0154
MARKET CAP
--
P/E (TTM)
-0.0037
1D
5D
1M
3M
1Y
5Y
1D
Cingulate reports Q1 results
Seeking Alpha · 3d ago
Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate
Benzinga · 3d ago
Cingulate FY26 Q1 net loss widens 141.7% to $9.31 million
PUBT · 3d ago
Cingulate Q1 net loss widens more than expected on commercial preparations
Reuters · 3d ago
Press Release: Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Dow Jones · 3d ago
Weekly Report: what happened at CING last week (0504-0508)?
Weekly Report · 6d ago
Weekly Report: what happened at CING last week (0427-0501)?
Weekly Report · 05/04 10:30
Biotech Stocks Facing FDA Decision In May 2026
NASDAQ · 04/28 12:01
More
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.

Webull offers Cingulate Inc stock information, including NASDAQ: CINGW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CINGW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CINGW stock methods without spending real money on the virtual paper trading platform.